Cancer therapy: back to metabolism.
Malhi
Harmeet
H
Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
Gores
Gregory J
GJ
D015107:4-Butyrolactone / Q000031:analogs & derivatives* / Q000494:pharmacology; D006528:Carcinoma, Hepatocellular / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D002453:Cell Cycle / Q000187:drug effects*; D064429:Fatty Acid Synthases / Q000037:antagonists & inhibitors*; D005227:Fatty Acids / Q000378:metabolism*; D006801:Humans; D008113:Liver Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D016159:Tumor Suppressor Protein p53 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D019014:fas Receptor / Q000037:antagonists & inhibitors / Q000378:metabolism; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism
C406734:4-methylene-2-octyl-5-oxofuran-3-carboxylic acid; D005227:Fatty Acids; D016159:Tumor Suppressor Protein p53; D019014:fas Receptor; D064429:Fatty Acid Synthases; D048051:p38 Mitogen-Activated Protein Kinases; D015107:4-Butyrolactone